Arrowstreet Capital’s Quince Therapeutics QNCX Stock Holding History

Arrowstreet Capital’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-297	Closed	-$749K	–	1472
2021 Q4	$749K	Buy	+297	New	+$1.81M	﹤0.01%	1214

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's QNCX Position: Q1 2022 in Review

Arrowstreet Capital sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 297 shares — an estimated $749K sold.

Arrowstreet Capital first reported a position in QNCX in Q4 2021 and held it in 1 quarter. The position peaked at $749K in Q4 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

Arrowstreet Capital reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
Arrowstreet Capital sold 297 Quince Therapeutics shares in Q1 2022, an estimated $749K.
Arrowstreet Capital first reported a position in Quince Therapeutics in Q4 2021 and held it in 1 quarter.
Arrowstreet Capital's Quince Therapeutics position peaked at $749K in Q4 2021.
85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on Arrowstreet Capital's 13F filing for Q1 2022, filed 13 May 2022.